

Watsamon Jantarabenjakul

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9216948/publications.pdf>

Version: 2024-02-01

42
papers

744
citations

840119

11
h-index

580395

25
g-index

44
all docs

44
docs citations

44
times ranked

969
citing authors

#	ARTICLE	IF	CITATIONS
1	Federated learning for predicting clinical outcomes in patients with COVID-19. <i>Nature Medicine</i> , 2021, 27, 1735-1743.	15.2	300
2	Evaluating the efficiency of specimen pooling for PCR-based detection of COVID-19. <i>Journal of Medical Virology</i> , 2020, 92, 2193-2199.	2.5	77
3	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. <i>PLoS ONE</i> , 2020, 15, e0240502.	1.1	68
4	COVID-19 vaccine acceptance, hesitancy, and determinants among physicians in a university-based teaching hospital in Thailand. <i>BMC Infectious Diseases</i> , 2021, 21, 1174.	1.3	39
5	Association of Empiric Antibiotic Regimen Discordance With 30-Day Mortality in Neonatal and Pediatric Bloodstream Infection—A Global Retrospective Cohort Study. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 137-143.	1.1	27
6	Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at risk for HIV in Thailand: a randomized control trial. <i>Journal of the International AIDS Society</i> , 2020, 23, e25564.	1.2	23
7	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. <i>PLoS ONE</i> , 2021, 16, e0246864.	1.1	20
8	Short-term immune response after inactivated SARS-CoV-2 (CoronaVac®, Sinovac) and ChAdOx1 nCoV-19 (Vaxzevria®, Oxford-AstraZeneca) vaccinations in health care workers. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2022, , .	0.2	20
9	Optimizing Vancomycin Use Through Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1597-1605.	1.0	19
10	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with BNT162b2 or ChAdOx1 in Health Care Workers. <i>Vaccines</i> , 2022, 10, 639.	2.1	18
11	Host genetic factors of COVID-19 susceptibility and disease severity in a Thai population. <i>Journal of Human Genetics</i> , 2022, 67, 295-301.	1.1	15
12	Low risk of neurodevelopmental impairment among perinatally acquired HIV-infected preschool children who received early antiretroviral treatment in Thailand. <i>Journal of the International AIDS Society</i> , 2019, 22, e25278.	1.2	10
13	Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. <i>Vaccine</i> , 2016, 34, 5279-5283.	1.7	9
14	Skin manifestations in COVID-19: The tropics experience. <i>Journal of Dermatology</i> , 2020, 47, e444-e446.	0.6	9
15	Cold agglutinin disease following SARS-CoV-2 and <i>Mycoplasma pneumoniae</i> infections. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2402-2405.	0.2	8
16	Gaps in the elimination of congenital syphilis in a tertiary care center in Thailand. <i>Pediatrics International</i> , 2020, 62, 330-336.	0.2	6
17	Behavioral problems in perinatally HIV-infected young children with early antiretroviral therapy and HIV-exposed uninfected young children: prevalence and associated factors. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 429-437.	0.6	5
18	CD4/CD8 Ratio Recovery of Children and Adolescents Living With HIV With Virological Suppression: A Prospective Cohort Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 88-96.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 66-70.	1.1	4
20	Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 1045-1050.	1.1	4
21	Diagnostic Accuracy of Loop-Mediated Isothermal Amplification (TB-LAMP) for Tuberculosis in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 9-15.	0.6	4
22	Multiple clades of SARS-CoV-2 were introduced to Thailand during the first quarter of 2020. <i>Microbiology and Immunology</i> , 2021, 65, 405-409.	0.7	4
23	Pharmacokinetics and Safety of WHO-Recommended Dosage and Higher Dosage of Levofloxacin for Tuberculosis Treatment in Children: a Pilot Study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 603-608.	1.5	4
24	A randomized open-label trial of 2-dose or 3-dose pre-exposure rabies prophylaxis among Thai children. <i>Vaccine</i> , 2019, 37, 5307-5313.	1.7	3
25	State of the Mind: Growing up with HIV. <i>Paediatric Drugs</i> , 2020, 22, 511-524.	1.3	3
26	Efficacy of chlorhexidine patches on central line-associated bloodstream infections in children. <i>Pediatrics International</i> , 2020, 62, 789-796.	0.2	3
27	High prescribing rates of third-generation cephalosporins in children hospitalized with acute lower respiratory infections at a university hospital. <i>International Journal of Infectious Diseases</i> , 2021, 102, 369-374.	1.5	3
28	Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion. <i>Respirology Case Reports</i> , 2021, 9, e0733.	0.3	3
29	Acceptance and Outcome of Interventions in Meropenem De-escalation ASP in Pediatrics. <i>Pediatrics International</i> , 2021, 63, 1458-1465.	0.2	3
30	Pediatric and Neonatal Invasive Candidiasis. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 96-102.	1.1	3
31	A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222. <i>Vaccines</i> , 2022, 10, 914.	2.1	3
32	Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 152-156.	1.1	2
33	Immunogenicity of 2-dose pre-exposure rabies vaccine co-administered with quadrivalent influenza vaccine in children. <i>International Journal of Infectious Diseases</i> , 2021, 112, 89-95.	1.5	2
34	Prevention of Emerging Infections in Children. <i>Pediatric Clinics of North America</i> , 2022, 69, 185-202.	0.9	2
35	A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age. <i>Vaccine</i> , 2022, 40, 2352-2361.	1.7	2
36	Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand. <i>Journal of the International AIDS Society</i> , 2022, 25, e25862.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 122, 725-732.	1.5	2
38	Pharmacokinetics of Rilpivirine and 24-Week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-Infected Adolescents. <i>Antiviral Therapy</i> , 2018, 23, 259-265.	0.6	1
39	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. , 2020, 15, e0240502.		0
40	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. , 2020, 15, e0240502.		0
41	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. , 2020, 15, e0240502.		0
42	Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. , 2020, 15, e0240502.		0